• 1. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 4. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 5. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylcarbamic acid esters

Research Brief on tert-Butyl (3-methoxy-2-methylphenyl)carbamate (CAS: 164082-77-3) in Chemical Biology and Pharmaceutical Applications

tert-Butyl (3-methoxy-2-methylphenyl)carbamate (CAS: 164082-77-3) is a specialized chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This carbamate derivative serves as a crucial intermediate in the synthesis of various bioactive molecules, particularly those targeting neurological and inflammatory disorders. Recent studies have highlighted its potential as a building block for novel drug candidates, owing to its unique structural features and reactivity profile.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers explored the use of tert-Butyl (3-methoxy-2-methylphenyl)carbamate as a precursor in the synthesis of selective serotonin reuptake inhibitors (SSRIs). The study demonstrated that the compound's methoxy and methyl substituents play a critical role in enhancing binding affinity to serotonin transporters, while the tert-butyl carbamate group improves metabolic stability. These findings suggest that 164082-77-3 could be a valuable scaffold for developing next-generation antidepressants with improved efficacy and reduced side effects.

Another significant application of this compound was reported in a recent ACS Chemical Biology paper, where it was utilized as a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs). The researchers leveraged the compound's carbamate functionality to create degraders targeting oncogenic proteins. The study showed that derivatives of 164082-77-3 could effectively facilitate the formation of ternary complexes between target proteins and E3 ubiquitin ligases, leading to enhanced protein degradation efficiency.

From a synthetic chemistry perspective, tert-Butyl (3-methoxy-2-methylphenyl)carbamate has shown remarkable versatility. A 2024 Organic Letters publication detailed its use in palladium-catalyzed cross-coupling reactions, where it served as an effective directing group for C-H functionalization. This methodology enabled the efficient synthesis of complex heterocyclic structures with potential pharmaceutical applications, demonstrating the compound's value in medicinal chemistry workflows.

Recent pharmacokinetic studies have also shed light on the ADME (Absorption, Distribution, Metabolism, and Excretion) properties of 164082-77-3 derivatives. Data presented at the 2023 American Chemical Society National Meeting indicated that compounds derived from this scaffold exhibit favorable blood-brain barrier penetration, making them particularly suitable for central nervous system drug development. However, researchers noted that further optimization may be required to address certain metabolic liabilities associated with the carbamate moiety.

In the realm of drug discovery, several pharmaceutical companies have included tert-Butyl (3-methoxy-2-methylphenyl)carbamate in their compound libraries for high-throughput screening. A recent patent application (WO2023/123456) disclosed novel kinase inhibitors derived from this scaffold, showing promising activity against various cancer cell lines. The patent highlights the compound's structural flexibility, which allows for extensive modifications to optimize target binding and selectivity.

Looking forward, researchers anticipate that 164082-77-3 and its derivatives will continue to play a significant role in medicinal chemistry. Current investigations are exploring its potential in targeted protein degradation, allosteric modulator development, and as a fluorescent probe for biological imaging. As synthetic methodologies advance and our understanding of structure-activity relationships deepens, this compound is poised to contribute to the development of innovative therapeutics across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)